BR112021023632A2 - Métodos e composições para gerar óxido nítrico e usos do mesmo para entregar óxido nítrico através do trato respiratório - Google Patents

Métodos e composições para gerar óxido nítrico e usos do mesmo para entregar óxido nítrico através do trato respiratório

Info

Publication number
BR112021023632A2
BR112021023632A2 BR112021023632A BR112021023632A BR112021023632A2 BR 112021023632 A2 BR112021023632 A2 BR 112021023632A2 BR 112021023632 A BR112021023632 A BR 112021023632A BR 112021023632 A BR112021023632 A BR 112021023632A BR 112021023632 A2 BR112021023632 A2 BR 112021023632A2
Authority
BR
Brazil
Prior art keywords
nitric oxide
respiratory tract
optionally
compositions
methods
Prior art date
Application number
BR112021023632A
Other languages
English (en)
Portuguese (pt)
Inventor
Barry Wood Christopher
Semple Munro Hugh
Original Assignee
Thirty Respiratory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1907971.4A external-priority patent/GB201907971D0/en
Priority claimed from GB201915277A external-priority patent/GB201915277D0/en
Priority claimed from GBGB2005979.6A external-priority patent/GB202005979D0/en
Application filed by Thirty Respiratory Ltd filed Critical Thirty Respiratory Ltd
Publication of BR112021023632A2 publication Critical patent/BR112021023632A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
BR112021023632A 2019-06-04 2020-06-02 Métodos e composições para gerar óxido nítrico e usos do mesmo para entregar óxido nítrico através do trato respiratório BR112021023632A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1907971.4A GB201907971D0 (en) 2019-06-04 2019-06-04 Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract
GB201915277A GB201915277D0 (en) 2019-10-22 2019-10-22 Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract
GBGB2005979.6A GB202005979D0 (en) 2020-04-23 2020-04-23 Methods and compositions for generating nitric oxide and uses therof to deliver nitric oxide via the respiratory tract
PCT/GB2020/051329 WO2020245574A1 (en) 2019-06-04 2020-06-02 Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract

Publications (1)

Publication Number Publication Date
BR112021023632A2 true BR112021023632A2 (pt) 2022-04-19

Family

ID=71092559

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021023632A BR112021023632A2 (pt) 2019-06-04 2020-06-02 Métodos e composições para gerar óxido nítrico e usos do mesmo para entregar óxido nítrico através do trato respiratório

Country Status (9)

Country Link
US (1) US20220257642A1 (enExample)
EP (1) EP3980032A1 (enExample)
JP (1) JP7686578B2 (enExample)
CN (1) CN114126629B (enExample)
AU (1) AU2020286987B2 (enExample)
BR (1) BR112021023632A2 (enExample)
CA (1) CA3142109A1 (enExample)
GB (1) GB2599818B (enExample)
WO (1) WO2020245574A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2748141B1 (en) 2011-08-24 2017-12-06 Novan, Inc. Tunable nitric oxide-releasing macromolecules having multiple nitric oxide donor structures
US10517817B2 (en) 2013-05-09 2019-12-31 Syk Technologies, Llc Deep topical systemic nitric oxide therapy apparatus and method
EP3030266B1 (en) 2013-08-08 2020-10-28 Novan Inc. Topical compositions and methods of using the same
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
WO2017132275A1 (en) 2016-01-27 2017-08-03 Syk Technologies, Llc Nitric oxide topical application apparatus and methods
WO2021188651A1 (en) 2020-03-19 2021-09-23 Friedman Joel M Novel approach to sustained production and delivery of nitric oxide and s-nitrosothiols
EP4138795A1 (en) * 2020-04-23 2023-03-01 Thirty Respiratory Limited Nitric oxide or nitric oxide releasing compositions for use in treating sars-cov and sars-cov-2
GB2610721B (en) * 2020-04-23 2024-07-31 Thirty Respiratory Ltd Compositions for treating and combatting tuberculosis
JP7613776B2 (ja) 2020-11-09 2025-01-15 アルバート アインシュタイン カレッジ オブ メディシン 経皮送達製剤
US12059493B2 (en) 2020-11-09 2024-08-13 Albert Einstein College Of Medicine Transdermal delivery formulations
US12151019B2 (en) 2020-11-09 2024-11-26 Albert Einstein College Of Medicine Compositions for blood storage and transfusions
US20220243065A1 (en) * 2021-01-29 2022-08-04 Joel Mendelsberg Filament for 3-d printing of chewable dog toys and treats
GB202101543D0 (en) 2021-02-04 2021-03-24 Thirty Respiratory Ltd Vaping e-liquid composition and the use thereof
US20230390508A1 (en) * 2021-07-22 2023-12-07 Noxy Health Products, Inc. Nitric oxide nasal delivery apparatus and methods
US20230022521A1 (en) * 2021-07-22 2023-01-26 Syk Technologies Llc Nitric oxide nasal delivery apparatus and methods
WO2023034787A1 (en) * 2021-08-30 2023-03-09 Albert Einstein College Of Medicine Nitric oxid-releasing device
US20250049841A1 (en) * 2021-12-17 2025-02-13 Lnhc, Inc. Nitric oxide-releasing nasal compositions and methods of use thereof
GB202302117D0 (en) * 2023-02-14 2023-03-29 Thirty Respiratory Ltd Compositions, kits and combinations
GB202302118D0 (en) * 2023-02-14 2023-03-29 Thirty Therapeutics Ltd Compositions, kits and combinations
WO2025257398A1 (en) * 2024-06-14 2025-12-18 Universite De Tours Dicarboxylic acids and esters thereof for use in the treatment of a viral lung infection
GB2644374A (en) 2024-09-20 2026-04-08 Thirty Holdings Ltd Compositions and kits for generating nitric oxide

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826255A (en) 1972-06-22 1974-07-30 Hudson Oxygen Therapy Sales Co Intermittent positive pressure breathing manifold
YU41046B (en) 1974-08-22 1986-10-31 Schering Ag Medicine inholating device
US4130639A (en) 1977-09-28 1978-12-19 Ethicon, Inc. Absorbable pharmaceutical compositions based on isomorphic copolyoxalates
US4268460A (en) 1977-12-12 1981-05-19 Warner-Lambert Company Nebulizer
US4253468A (en) 1978-08-14 1981-03-03 Steven Lehmbeck Nebulizer attachment
US4263907A (en) 1979-05-14 1981-04-28 Lindsey Joseph W Respirator nebulizer
US4510929A (en) 1982-04-30 1985-04-16 Bordoni Maurice E Disposable radioactive aerosol inhalation apparatus
US4649911A (en) 1983-09-08 1987-03-17 Baylor College Of Medicine Small particle aerosol generator for treatment of respiratory disease including the lungs
US4624251A (en) 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
NZ241579A (en) 1991-03-25 1994-04-27 Becton Dickinson Co Antimicrobial formulations for treating the skin
US5164740A (en) 1991-04-24 1992-11-17 Yehuda Ivri High frequency printing mechanism
ATE155695T1 (de) 1991-11-07 1997-08-15 Ritzau Pari Werk Gmbh Paul Vernebler insbesondere zur anwendung in geräten für die inhalationstherapie
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US5709202A (en) 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
WO1995009605A1 (en) 1993-10-06 1995-04-13 Henkel Corporation Improving phenolic disinfectant cleaning compositions with alkylpolyglucoside surfactants
US6034133A (en) 1993-11-05 2000-03-07 The University Of Virginia Patents Foundation Use of a virucidal hand lotion to prevent the spread of rhinovirus colds
PL180769B1 (pl) 1994-02-21 2001-04-30 Univ Aberdeen Postać dawkowana do miejscowego leczenia stanów powodowanych przez drobnoustroje, sposób sterylizacji obiektów i kompozycja sterylizująca
GB9804469D0 (en) 1998-03-02 1998-04-29 Univ Aberdeen Antiviral composition
US5681802A (en) 1994-06-01 1997-10-28 Lever Brothers Company, Division Of Conopco, Inc. Mild antimicrobial liquid cleansing formulations comprising buffering compound or compounds as potentiator of antimicrobial effectiveness
US5635462A (en) 1994-07-08 1997-06-03 Gojo Industries, Inc. Antimicrobial cleansing compositions
US5776430A (en) 1994-11-01 1998-07-07 Calgon Vestal, Inc. Topical antimicrobial cleanser containing chlorhexidine gluconate and alcohol
US5648101A (en) * 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
EP0799017A1 (en) * 1994-11-15 1997-10-08 Osmotics Corporation Skin care compositions and methods
US5702754A (en) 1995-02-22 1997-12-30 Meadox Medicals, Inc. Method of providing a substrate with a hydrophilic coating and substrates, particularly medical devices, provided with such coatings
WO1996025918A1 (en) 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
ZA962455B (en) 1995-03-31 1996-10-02 B Eugene Guthery Fast acting and persistent topical antiseptic
US5758637A (en) 1995-08-31 1998-06-02 Aerogen, Inc. Liquid dispensing apparatus and methods
US5586550A (en) 1995-08-31 1996-12-24 Fluid Propulsion Technologies, Inc. Apparatus and methods for the delivery of therapeutic liquids to the respiratory system
US5823179A (en) 1996-02-13 1998-10-20 1263152 Ontario Inc. Nebulizer apparatus and method
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5955408A (en) 1996-07-10 1999-09-21 Steris Inc. Triclosan skin wash with enhanced efficacy
US5906202A (en) 1996-11-21 1999-05-25 Aradigm Corporation Device and method for directing aerosolized mist to a specific area of the respiratory tract
US6349719B2 (en) 1997-02-24 2002-02-26 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
US6258368B1 (en) 1997-06-04 2001-07-10 The Procter & Gamble Company Antimicrobial wipes
US5855564A (en) 1997-08-20 1999-01-05 Aradigm Corporation Aerosol extrusion mechanism
CA2301569A1 (en) 1997-10-08 1999-04-15 Martin P. Redmon Dosage form for aerosol administration
DK1129741T3 (da) 1997-11-19 2006-08-07 Microflow Eng Sa Forstövningsindretning til inhalator
US6192876B1 (en) 1997-12-12 2001-02-27 Astra Aktiebolag Inhalation apparatus and method
US6258371B1 (en) 1998-04-03 2001-07-10 Medtronic Inc Method for making biocompatible medical article
US6103275A (en) 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
EP1100556B1 (en) 1998-07-31 2003-11-12 First Water Limited Bioadhesive compositions and biomedical electrodes containing them
GB2343122B (en) 1998-10-26 2003-01-08 Medic Aid Ltd Improvements in and relating to nebulisers
US6070575A (en) 1998-11-16 2000-06-06 Aradigm Corporation Aerosol-forming porous membrane with certain pore structure
US6584971B1 (en) 1999-01-04 2003-07-01 Medic-Aid Limited Drug delivery apparatus
GB9905425D0 (en) 1999-03-09 1999-05-05 Queen Mary & Westfield College Pharmaceutical composition
JP2000355667A (ja) 1999-04-14 2000-12-26 Seiko Epson Corp カラーインクジェット記録用水系顔料インクセット、カラーインクジェット記録方法、及びカラーインクジェット記録物
US6338443B1 (en) 1999-06-18 2002-01-15 Mercury Enterprises, Inc. High efficiency medical nebulizer
US6107261A (en) 1999-06-23 2000-08-22 The Dial Corporation Compositions containing a high percent saturation concentration of antibacterial agent
WO2001076671A2 (en) 2000-04-11 2001-10-18 Trudell Medical International Aerosol delivery apparatus with positive expiratory pressure capacity
GB0021317D0 (en) 2000-08-30 2000-10-18 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition
GB0022084D0 (en) * 2000-09-08 2000-10-25 Univ Aberdeen Treatment of multiply antibiotic-resistant organisms
US6601581B1 (en) 2000-11-01 2003-08-05 Advanced Medical Applications, Inc. Method and device for ultrasound drug delivery
GB0116860D0 (en) * 2001-07-10 2001-09-05 Univ Montfort Gel compositions
GB0119011D0 (en) 2001-08-03 2001-09-26 Univ Aberdeen Treatment of nail infections
US7135189B2 (en) 2001-08-23 2006-11-14 Boston Scientific Scimed, Inc. Compositions and techniques for localized therapy
GB0125222D0 (en) 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
US7066356B2 (en) 2002-08-15 2006-06-27 Ecolab Inc. Foam soap dispenser for push operation
WO2005081752A2 (en) 2004-02-09 2005-09-09 Amulet Pharmaceuticals, Inc. Nitric oxide-releasing polymers
CA2602411C (en) * 2005-03-23 2015-02-24 Oculus Innovative Sciences, Inc. Method of treating second and third degree burns using oxidative reductive potential water solution
CN1698584A (zh) * 2005-04-30 2005-11-23 山东京卫制药有限公司 含活性成分的鼻喷雾凝胶剂
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
WO2007007115A2 (en) 2005-07-14 2007-01-18 First Water Limited Treatment of chronic ulcerous skin lesions
CN101028229B (zh) 2006-03-02 2012-09-05 北京富丽华德生物医药科技有限公司 基于一氧化氮的新型化妆品
CN101062050A (zh) 2006-04-29 2007-10-31 北京尼奥克斯生物科技有限公司 一种基于一氧化氮的新型生发产品及其制备方法
EP2040542A2 (en) 2006-05-30 2009-04-01 The Dial Corporation Compositions having a high antiviral effeicacy
WO2008110872A2 (en) 2006-06-23 2008-09-18 Foamix Ltd. Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
WO2008066810A2 (en) * 2006-11-27 2008-06-05 Novartis Ag Pleasant tasting dry powder compositions suitable for pulmonary delivery
GB0700911D0 (en) 2007-01-17 2007-02-28 First Water Ltd Treatment of inflammation and the complement and kinin cascades in a patient, particularly in chronic ulcerous skin lesions
GB0700908D0 (en) 2007-01-17 2007-02-28 First Water Ltd Inhibition of proteases, particularly in the treatment of chronic ulcerous skin lesions
GB0715556D0 (en) 2007-08-09 2007-09-19 Insense Ltd Improvements relating to skin dressings
US9278157B2 (en) * 2007-08-09 2016-03-08 Insense Limited Nitric oxide-generating skin dressings
US20090196930A1 (en) * 2007-12-27 2009-08-06 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide -donating compounds and uses thereof
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
EP2575829A4 (en) * 2010-06-07 2014-04-30 Topical Pharma Ab KIT FOR THE TREATMENT OF ONYCHOMYCOSIS BY STICKOXIDE
WO2013026000A1 (en) * 2011-08-17 2013-02-21 Board Of Regents, The University Of Texas System Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system
EP2790670A1 (en) * 2011-12-12 2014-10-22 Leo Laboratories Limited Gel compositions
US20130200109A1 (en) 2012-02-06 2013-08-08 Frank Yang Foaming soap dispensers and methods
CN103622917B (zh) 2012-08-23 2017-12-29 尼奥克斯(文莱)控股有限公司 基于微囊化亚硝酸盐和酸化水凝胶的延时产生一氧化氮的系统和方法
US10517817B2 (en) 2013-05-09 2019-12-31 Syk Technologies, Llc Deep topical systemic nitric oxide therapy apparatus and method
GB201309091D0 (en) 2013-05-20 2013-07-03 Edixomed Ltd Dressing system
GB201309092D0 (en) * 2013-05-20 2013-07-03 Edixomed Ltd Transdermal delivery system
CA2946828A1 (en) 2014-03-14 2015-09-17 Nitric Solutions, Inc. Treating diseases using nitric oxide releasing solutions
ITUB20154719A1 (it) * 2015-10-21 2017-04-21 Glano Tech Ltd Formulazione per il rilascio di ossido nitrico
WO2017132275A1 (en) 2016-01-27 2017-08-03 Syk Technologies, Llc Nitric oxide topical application apparatus and methods
PL3579888T3 (pl) * 2017-02-09 2024-05-27 Noxsano Inc. Kompozycje wytwarzające elektrochemiczny transmiter oraz sposoby ich stosowania oraz opatrunki i układy leczenia, w których się je stosuje
CN108524570A (zh) * 2018-06-28 2018-09-14 遵义医学院 一种具有促进皮肤溃疡创面修复的复方艾纳香生肌凝胶剂及其制备方法

Also Published As

Publication number Publication date
JP2023510662A (ja) 2023-03-15
CN114126629B (zh) 2024-08-30
CA3142109A1 (en) 2020-12-10
EP3980032A1 (en) 2022-04-13
AU2020286987A1 (en) 2021-12-16
US20220257642A1 (en) 2022-08-18
GB2599818B (en) 2024-01-31
WO2020245574A1 (en) 2020-12-10
AU2020286987B2 (en) 2025-09-11
GB2599818A (en) 2022-04-13
JP7686578B2 (ja) 2025-06-02
CN114126629A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
BR112021023832A8 (pt) Métodos e composições para geração de óxido nítrico e usos dos mesmos
NZ759766A (en) Use of lactic acid bacteria to treat or prevent at least one of postnatal depression and postnatal anxiety
MX2012012225A (es) Profármacos de agentes tearapéuticos de liberación de óxido nítrico.
BR112014011896A2 (pt) agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr)
BR112022024120A2 (pt) Derivado de piridina-pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
BR112014009528A8 (pt) métodos e composições para tratar eritropoiese ineficaz
BR112018005454A2 (pt) administração de potencializadores de cftr deuterados
BR112012024349A2 (pt) métodos de tratamento de carcinoma hepatocelular
BR112018072339A2 (pt) tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados
BR112015023520A2 (pt) purificação do conjugado de anticorpo-fármaco (adc)
BR112013020620A2 (pt) análogos de ácido 4-hidroxibutírico
BR112015008847A2 (pt) composições compreendendo ácido peróxido
BR112015025766A2 (pt) derivado de nucleosídeo altamente ativo para o tratamento de hcv
JP2023510662A5 (enExample)
BR112017015773A2 (pt) muteína de lipocalina, muteína de hngal, molécula de ácido nucleico, célula hospedeira, método para produzir a muteína de hngal, composição farmacêutica, kit, uso da muteína de hngal, uso da muteína de hngal, método para ligar ang-2 em um indivíduo, método para inibir angiogênese em um indivíduo, método para tratar, prevenir ou melhorar uma doença e método para inibir ou reduzir angiogênese em um indivíduo
BR112017018328A2 (pt) anticorpo de ligação ao tfpi, método para produzir e composição compreendendo o mesmo
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
BRPI0903359B8 (pt) composição farmacêutica de metformina, ácido acetilsalicílico e composto de serotonina para o tratamento do câncer
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
BR112019000293A2 (pt) formas sólidas de um estimulador de sgc
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112022011388A2 (pt) Métodos para tratar ou prevenir asma alérgica administrando um antagonista de il-33 e/ou um antagonista de il-4r
BR112019003136A2 (pt) forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo
MX2021005904A (es) Inhibidores de la ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa.
BR112012019921A2 (pt) composições líquidas compreendendo um agente de resfriamento não-metol e um espessante para tratamento de um sintoma respiratório.

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]